General Practice Research Database Seroquel XR Safety Study
Launched by ASTRAZENECA · Oct 4, 2011
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Episodes of new use (\>/=1 prescription) of quetiapine XR or other study drugs
- Exclusion Criteria:
- • Less than two years of recorded history before the start of the marketing of quetiapine XR (or cohort entry date)
- • If the duration and dose of the antipsychotic drug cannot be determined
Trial Officials
Christoph R Meier, PROF DR PHIL
Principal Investigator
University hospital of Basel, Switzerland
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
